Tilray, Inc. Reports First Quarter Fiscal Year 2022 Financial Results

Rhea-AI Summary

Tilray, Inc. reported net revenue growth of 43% to $168 million for the first fiscal quarter ending August 31, 2021, driven by higher cannabis, beverage alcohol, and wellness revenues. The company achieved its tenth consecutive quarter of positive adjusted EBITDA, totaling $12.7 million, a 58% increase year-over-year. Gross profit rose 46% to $51 million. Tilray aims for at least $80 million in cost-saving synergies from its Aphria merger. It maintains a leading market share in Canada and Germany, positioning itself for growth amid global cannabis legalization.

Positive

• Net revenue increased 43% to $168 million.
• Gross profit increased 46% to $51 million.
• Achieved tenth consecutive quarter of positive adjusted EBITDA, totaling $12.7 million.
• On-track for at least $80 million in cost-saving synergies from Aphria merger.
• Maintained #1 market share in Canada and Germany for medical cannabis.

Negative

• Net loss of $34.6 million compared to $21.7 million in the prior year.

Net Revenue and Gross Profit Increased 43% and 46%, Respectively, for Largest Global Cannabis Cultivator

10^th Consecutive Quarter of Positive Adjusted EBITDA

$55 Million in Cost-Savings Achieved On a Run-Rate Basis To Date; On-track for at Least $80 Million in Cost-Savings from Aphria and Tilray Synergies

#1 Leading Market Share in Canada¹ with Comprehensive Portfolio of Medical and Adult-Use Cannabis Brands, International Market Leader and #1 in Germany² with Medical Cannabis Extracts

NEW YORK & LEAMINGTON, Ontario--(BUSINESS WIRE)-- Tilray, Inc. (“Tilray” or the “Company”) (Nasdaq: TLRY; TSX: TLRY), a leading global cannabis-lifestyle and consumer packaged goods company, today reported financial results for the first fiscal quarter ended August 31, 2021. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated, and presented in accordance with accounting principles generally accepted in the U.S. (“GAAP”).

Irwin D. Simon, Tilray’s Chairman and Chief Executive Officer, stated, “Tilray’s first quarter 2022 results affirm that, amid the paradigm shift towards global cannabis legalization, we are unquestionably executing against two key objectives. The first is maximizing near-term profitability through leadership in both higher-margin international medical markets and in Canada, complemented by incremental growth at SweetWater and Manitoba Harvest in the U.S. These efforts are augmented by the cost benefits of our increased scale that we are realizing through our integration process. The tangible results include our tenth consecutive quarter of positive adjusted EBITDA and meaningful net revenue growth despite continued impacts from COVID-19 in Canada as retail cannabis stores only began opening in mid-June.”

Mr. Simon continued, “The second objective is to fully realize the promise and potential of Tilray by capitalizing on the nearly $200 billion global cannabis market opportunity. We believe we are ideally-positioned to succeed due to our global consumer-packaged goods expertise and scale, our diverse portfolio of brands, our reputation as a trusted supplier of high-quality cannabis, battle-tested leadership and a relentless focus on driving sustainable shareholder value. We look forward to accelerating our momentum as we build the leading CPG business in the global cannabis industry.”

Financial Highlights – First Quarter Fiscal 2022

• Net revenue increased 43% to $168 million during the first quarter from $117 million in the prior year quarter. The increase was driven by 38% growth in net cannabis revenue to $70 million, net beverage alcohol revenue of $15 million following the SweetWater acquisition on November 25, 2020, and wellness revenue of $15 million from Manitoba Harvest.
• Maintained #1 market share in Canada³ with leading portfolio of comprehensive medical cannabis and adult-use brands, including top position in cannabis flower and pre-rolls; five Tilray brands rank in top five brands across all adult-use product categories.
• International market leader and #1 in Germany⁴ with medical cannabis extracts.
• Net loss of $34.6 million during the first quarter compared to net loss of $21.7 million in the prior year quarter.
• Adjusted EBITDA of $12.7 million in the first quarter 2022, 58% growth compared to the prior year quarter, and the tenth consecutive quarter of positive Adjusted EBITDA. If Adjusted EBITDA were normalized for Aphria’s production costs, metric would have been closer to $17 million.
• Gross profit increased 46% to $51 million from $35 million in the prior year quarter.
• Adjusted gross margin in the cannabis segment has remained strong at 43%.
• Cost-saving synergies of $55 million achieved on a run-rate basis to date, with actual cash-savings close to $20 million. On-track for at least $80 million in cost-savings from Aphria and Tilray business combination synergies.

Strong First Quarter Momentum Across Segments

• On August 19, 2021, Tilray completed the acquisition of amended convertible notes in MedMen, a premier retailer in the $80 billion U.S. cannabis market – a potentially transformative step towards Tilray’s objective of leading the U.S. market when legalization allows.
• On August 17, 2021, Tilray launched medical cannabis edibles in Canada.
• On July 19, 2021, Tilray’s wholly owned subsidiary, SweetWater Brewing Company, announced the launch of 420 Imperial IPA, the first line extension of its flagship 420 brand.
• On July 12, 2021, SweetWater announced its West Coast expansion including a new Colorado Brewery and the opening of SweetWater Mountain Taphouse at Denver International Airport.
• On July 7, 2021, Tilray announced the completion and shipment of the first successful EU GMP-certified medical cannabis harvest grown in Germany for German distribution.
• On June 30, 2021, Tilray announced the launch of “Broken Coast BC Lager” – the first cross-brand product collaboration between Canadian craft-cannabis brand Broken Coast and SweetWater.
• On June 29, 2021, Tilray launched a new medical cannabis brand in Canada, Symbios, the inaugural brand developed to offer patients a broader spectrum of medical cannabis formats and cannabinoid ratios at a better price point.
• On June 25, 2021, Tilray’s leading Canadian cannabis brand, RIFF, launched new multi-pack of cannabis pre-rolls.

Ongoing Global Growth and Opportunity

The confluence of global cannabis legalization and the global economy’s emergence from COVID-19 lockdowns signal a period of enormous potential for Tilray – a leading cannabis company with the scale, reach and organic growth and M&A firepower to take full advantage of the massive global opportunity in cannabis. The Company’s business planning and integration are built around four key competitive differentiators:

• The industry’s broadest geographic footprint and operational scale - Tilray’s unparalleled and growing presence positions the Company to lead the global cannabis market including Europe, Latin America and Asia. As the largest cannabis cultivator in the world, Tilray remains to be one of the few companies with the capabilities to consistently supply high-quality cannabis to the global cannabis market.

• Leading market share in Canada, with a comprehensive portfolio of product offerings and carefully curated brands - Tilray plans to continue growing and strengthening its position as the #1 Canadian LP in total sales on a consolidated basis and to leverage its position, brands and new product innovation to expand its current cannabis retail market share in Canada of approximately 16% to its goal of 30% share by the end of fiscal year 2024.

• Tremendous international growth opportunities from a strong base - The European Union, which has nearly twice the population of the U.S. and where Tilray already has a very meaningful presence, represents a powerful growth market, and could potentially be a $1 billion business for the Company. With its operational and regulatory strengths, Tilray continues to unlock new opportunities across global geographies at a faster pace than competitors based on leadership, partnerships and operational scale.

• A leading U.S. CPG platform to be immediately leveraged for cannabis products upon federal legalization - In the U.S., Tilray has a strong consumer packaged goods presence and infrastructure with two strategic pillars: SweetWater, the 11^th largest craft brewer in the nation⁵ and leading lifestyle brand, and Manitoba Harvest, a pioneer in hemp, CBD and wellness products, with access to 17,000 stores in North America. Further, the investment the Company announced in August in the outstanding senior secured convertible notes of MedMen Enterprises Inc. (CSE: MMEN) (OTCQX: MMNFF), is a critical step towards delivering on its objective of leading the U.S. cannabis market upon federal legalization.

Conference Call

Tilray will host a conference call to discuss these results today at 8:30 a.m. ET. Investors interested in participating in the live call can dial (877) 407-0792 from Canada and the U.S. or (201) 689-8263 from international locations.

There will also be a simultaneous, live webcast available on the Investors section of the Company’s website at www.tilray.com. The webcast will be archived after the conference call.

About Tilray®

Tilray, Inc. (Nasdaq: TLRY; TSX: TLRY), is a leading global cannabis-lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia, and Latin America that is changing people's lives for the better – one person at a time – by inspiring and empowering the worldwide community to live their very best life by providing them with products that meet the needs of their mind, body, and soul and invoke a sense of wellbeing. Tilray’s mission is to be the trusted partner for its patients and consumers by providing them with a cultivated experience and health and wellbeing through high-quality, differentiated brands and innovative products. A pioneer in cannabis research, cultivation, and distribution, Tilray’s unprecedented production platform supports over 20 brands in over 20 countries, including comprehensive cannabis offerings, hemp-based foods, and alcoholic beverages.

For more information on how we open a world of wellbeing, visit www.Tilray.com.

Cautionary Statement Concerning Forward-Looking Statements

Certain statements contained in this press release constitute "forward-looking statements" within the meaning of federal securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements are predictions based on expectations and projections about future events and are not statements of historical fact. You can identify forward-looking statements by the use of forward-looking terminology such as "plan," "continue," "expect," "anticipate," "intend," "predict," "project," "estimate," "likely," "believe," "might," "seek," "may," "will," "remain," "potential," "can," "should," "could," "future" and similar expressions, or the negative of those expressions, or similar words or phrases that are predictions of or indicate future events or trends and that do not relate solely to historical matters. You can also identify forward-looking statements by discussions of the Company's strategic initiatives, including productivity and synergies initiatives, our future performance and results of operations.

Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, levels of activity, performance or achievements of the Company, or industry results, to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements, and you should not rely on them as predictions of future events. Forward-looking statements depend on assumptions, data or methods that may be incorrect or imprecise and may not be able to be realized. We do not guarantee that the transactions and events described will happen as described (or that they will happen at all). Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations for our business concerning, among other things, the Company’s ability to deliver short-term profitability through our increased scale, leadership in higher-margin international medical markets, and Canadian market share leadership; the Company’s ability to fully capitalize on the global cannabis market opportunity over the longer term; and the Company’s ability to become the world's leading cannabis-focused consumer branded company; the Company’s expectation to emerge as a consolidator in the global cannabis market; and Tilray’s plans to grow and strengthen its position as the #1 Canadian LP in total sales on a consolidated basis and its goal of 30% share by fiscal year 2024.

Certain material factors, estimates, goals, projections or assumptions were used in drawing the conclusions contained in the forward-looking statements throughout this communication. Many factors could cause actual results, performance or achievement to be materially different from any forward-looking statements, and other risks and uncertainties not presently known to the Company or that the Company deems immaterial could also cause actual results or events to differ materially from those expressed in the forward-looking statements contained herein. For a more detailed discussion of these risks and other factors, see the Annual Report on Form 10-K of Tilray for the fiscal year ended May 31, 2021. The forward-looking statements included in this communication are made as of the date of this communication and the Company does not undertake any obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities laws.

Use of Non-U.S. GAAP Financial Measures

This press release and the accompanying tables include non-GAAP financial measures, including adjusted gross margin, Adjusted EBITDA and adjusted free cash flow. Management believes that the non-GAAP financial measures presented provide useful additional information to investors about current trends in the Company's operations and are useful for period-over-period comparisons of operations. These non-GAAP financial measures should not be considered in isolation or as a substitute for the comparable GAAP measures. In addition, these non-GAAP measures may not be the same as similar measures provided by other companies due to potential differences in methods of calculation and items being excluded. They should be read only in connection with the Company's Consolidated Statements of Operations and Cash Flows presented in accordance with GAAP.

Adjusted EBITDA is calculated as net income (loss) before finance expense, net; non-operating expense (income), net; amortization; stock-based compensation; facility start-up and closure costs; inventory valuation adjustment; lease expense; and transaction costs. A reconciliation of Adjusted EBITDA to net loss, the most directly comparable GAAP measure, has been provided in the financial statement tables included below in this press release. Gross margin, excluding inventory valuation adjustments, is calculated as revenue less cost of sales adjusted to add back inventory valuation adjustments and amortization of inventory step-up, divided by revenue. A reconciliation of Gross margin, excluding inventory valuation adjustments, to gross margin, the most directly comparable GAAP measure, has been provided in the financial statement tables included below in this press release. Free cash flow is comprised of two GAAP measures deducted from each other which are net cash flow provided by (used in) operating activities less investments in capital and intangible assets. Adjusted free cash flow removes the cash impact of acquisitions from free cash flow. A reconciliation of net cash flow provided by (used in) operating activities to free cash flow and to adjusted cash flows, the most directly comparable GAAP measure, has been provided in the financial statement tables included below in this press release.

Consolidated Statements of Financial Position
(In thousands of United States dollars)		August 31, 2021				May 31, 2021
Assets
Current assets
Cash and cash equivalents		$	376,297			$	488,466
Accounts receivable, net			97,177				87,309
Inventory			251,507				256,429
Prepaids and other current assets			117,267				48,920
Convertible notes receivable			2,370				2,485
Total current assets			844,618				883,609
Capital assets			621,339				650,698
Right-of-use assets			17,783				18,267
Intangible assets			1,502,814				1,605,918
Goodwill			2,809,131				2,832,794
Interest in equity investees			4,062				8,106
Long-term investments			186,407				17,685
Other assets			198				8,285
Total assets		$	5,986,352			$	6,025,362
Liabilities
Current liabilities
Bank indebtedness		$	9,203			$	8,717
Accounts payable and accrued liabilities			190,213				212,813
Contingent consideration			61,494				60,657
Warrant liability			60,476				78,168
Escrow payable			170,799				—
Current portion of lease liabilities			3,808				4,264
Current portion of long-term debt			30,837				36,622
Total current liabilities			526,830				401,241
Long - term liabilities
Lease liabilities			53,331				53,946
Long-term debt			164,911				167,486
Convertible debentures			611,646				667,624
Deferred tax liability			239,373				265,845
Other liabilities			4,505				3,907
Total liabilities			1,600,596				1,560,049
Commitments and contingencies			—				—
Shareholders' equity
Common stock			46				46
Additional paid-in capital			4,795,879				4,792,406
Accumulated other comprehensive income			51,247				152,668
Deficit			(527,699	)			(486,050	)
Total Tilray shareholders' equity			4,319,473				4,459,070
Non-controlling interests			66,283				6,243
Total shareholders' equity			4,385,756				4,465,313
Total liabilities and shareholders' equity		$	5,986,352			$	6,025,362

Condensed Consolidated Statements of Net Loss and Comprehensive Loss
		Three months ended August 31,								Three months ended May 31,				Q1-22 over Q1-21						Q1-22 over Q4-21
(In thousands of United States dollars)		2021				2020				2021				Change			%Change			Change			%Change
Net revenue		$	168,023			$	117,490			$	142,236			$	50,533		43%			$	25,787		18%
Cost of goods sold			117,068				82,545				119,738				34,523		42%				(2,670	)	(2%)
Gross profit			50,955				34,945				22,498				16,010		46%				28,457		126%
Operating expenses:
General and administrative			49,487				25,972				32,847				23,515		91%				16,640		51%
Selling			7,432				5,817				8,525				1,615		28%				(1,093	)	(13%)
Amortization			30,739				4,127				16,100				26,612		645%				14,639		91%
Marketing and promotion			5,465				4,925				5,103				540		11%				362		7%
Research and development			785				120				358				665		554%				427		119%
Transaction costs			25,579				2,458				33,260				23,121		941%				(7,681	)	100%
Total operating expenses			119,487				43,419				96,193				76,068		175%				23,294		24%
Operating loss			(68,532	)			(8,474	)			(73,695	)			(60,058	)	709%				5,163		(7%)
Finance expense, net			(10,170	)			(5,736	)			(9,466	)			(4,434	)	77%				(704	)	7%
Non-operating income (expense), net			48,860				(13,359	)			121,510				62,219		(466%)				(72,650	)	(60%)
Loss before income taxes			(29,842	)			(27,569	)			38,349				(2,273	)	8%				(68,191	)	(178%)
Income taxes (recovery)			4,762				(5,825	)			4,744				10,587		(182%)				18		0%
Net loss		$	(34,604	)		$	(21,744	)		$	33,605			$	(12,860	)	59%			$	(68,209	)	(203%)
Weighted average number of common shares - basic			449,397,822				241,992,864				262,244,444
Weighted average number of common shares - diluted			449,397,822				241,992,864				262,244,444
Loss per share - basic		$	(0.08	)		$	(0.09	)		$	0.18
Loss per share - diluted		$	(0.08	)		$	(0.09	)		$	0.18

Net Revenue by Operating Segment
(In thousands of United States dollars)		Three months ended August 31, 2021				% of Total revenue			Three months ended August 31, 2020				% of Total revenue			Three months ended May 31, 2021				% of Total revenue
Cannabis revenue		$	70,449			42%			$	51,202			44%			$	53,703			38%
Distribution revenue			67,186			40%				66,288			56%				66,792			47%
Beverage alcohol revenue			15,461			9%				—			0%				15,947			11%
Wellness revenue			14,927			9%				—			0%				5,794			4%
Net revenue		$	168,023			100%			$	117,490			100%			$	142,236			100%

Net Cannabis Revenue by Market Channel
		Three months ended August 31,														Three months ended May 31,
(In thousands of United States dollars)		2021							2020							2021
Revenue from medical cannabis products		$	8,374			9%			$	6,380			10%			$	6,968					10%
Revenue from adult-use cannabis products			69,593			77%				56,948			85%				59,710					84%
Revenue from wholesale cannabis products			1,700			2%				3,792			6%				58					0%
Revenue from international cannabis products			10,266			11%				—			0%				4,622					6%
Total cannabis revenue			89,933							67,120							71,358
Excise taxes			(19,484	)		(22%)				(15,918	)		(24%)				(17,655	)				(25%)
Total cannabis net revenue		$	70,449						$	51,202						$	53,703

Other Financial Information: Gross Margin and Adjusted Gross Margin
(In thousands of United States dollars)		Three months ended August 31, 2021
Gross profit (excluding adjustments)		Cannabis				Beverage				Distribution				Wellness				Total
Gross revenue		$	89,933			$	16,483			$	67,186			$	14,927			$	188,529
Excise taxes			(19,484	)			(1,022	)			—				—				(20,506	)
Net revenue			70,449				15,461				67,186				14,927				168,023
Cost of goods sold			40,190				6,662				59,290				10,925				117,068
Gross profit		$	30,258			$	8,799			$	7,896			$	4,002			$	50,955
Gross margin			43	%			57	%			12	%			27	%			30	%
Adjusted gross profit		$	30,258			$	8,799			$	7,896			$	4,002			$	50,955
Adjusted gross margin			43	%			57	%			12	%			27	%			30	%
		Three months ended August 31, 2020
Gross profit (excluding adjustments)		Cannabis				Beverage				Distribution				Wellness				Total
Gross revenue		$	67,120			$	—			$	66,288			$	—			$	133,408
Excise taxes			(15,918	)			—				—				—				(15,918	)
Net revenue			51,202				—				66,288				—				117,490
Cost of goods sold			25,775				—				56,770				—				82,545
Gross profit		$	25,427			$	—			$	9,518			$	—			$	34,945
Gross margin			50	%			—	%			14	%			—	%			30	%
Adjusted gross profit		$	25,427			$	—			$	9,518			$	—			$	34,945
Adjusted gross margin			50	%			—	%			14	%			—	%			30	%
		Three months ended May 31, 2021
Gross profit (excluding adjustments)		Cannabis				Beverage				Distribution				Wellness				Total
Gross revenue		$	71,358			$	16,549			$	66,792			$	5,794			$	160,493
Excise taxes			(17,655	)			(602	)			—				—				(18,257	)
Net revenue			53,703				15,947				66,792				5,794				142,236
Cost of goods sold			49,731				5,349				60,425				4,233				119,738
Gross profit		$	3,972			$	10,598			$	6,367			$	1,561			$	22,498
Gross margin			7	%			66	%			10	%			27	%			16	%
Adjustments:
Inventory valuation adjustment			19,919				—				—				—				19,919
Adjusted gross profit		$	23,891			$	10,598			$	6,367			$	1,561			$	42,417
Adjusted gross margin			44	%			66	%			10	%			27	%			30	%
(There were no adjustments during the quarters ended August 31, 2021 and 2020.)

Other Financial Information: Adjusted Earnings before interest and amortization
		Three months ended August 31,								Three months ended May 31,
(In thousands of United States dollars)		2021				2020				2021
Net (loss) income		$	(34,604	)		$	(21,744	)		$	33,605
Income taxes			4,762				(5,825	)			4,744
Finance expense, net			10,170				5,736				9,466
Non-operating expense (income), net			(48,860	)			13,359				(121,510	)
Amortization			39,333				10,979				24,539
Stock-based compensation			9,417				2,850				5,937
Facility start-up and closure costs			6,200				—				2,056
Inventory valuation adjustment			—				—				19,919
Lease expense			700				240				303
Transaction costs			25,579				2,458				33,260
Adjusted EBITDA		$	12,697			$	8,053			$	12,319

Other Financial Information: Free cash flow and adjusted free cash flow
		Three months ended August 31,								Three months ended May 31,
(In thousands of United States dollars)		2021				2020				2021
Net cash provided by (used in) operating activities		$	(93,227	)		$	(56,100	)		$	8,281
Less: investments in capital and intangible assets			(16,316	)			(13,955	)			(4,943	)
Free cash flow		$	(109,543	)		$	(70,055	)		$	3,338
Cash expended related to acquisitions			48,390				—				—
Adjusted free cash flow		$	(61,153	)		$	(70,055	)		$	3,338

---

¹ Based on HiFyre data for the quarter June – August 2021.
² Insight Health NPI: Panel data of 5,500 pharmacies (29% coverage).
³ Based on HiFyre retail data.
⁴ Insight Health NPI: Panel data of 5,500 pharmacies (29% coverage)
⁵ The Brewers Association Top 50 Brewing Companies by Sales Volume Report for 2020.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211007005345/en/

Media: Berrin Noorata, news@tilray.com

Investors: Raphael Gross, +1-203-682-8253, Raphael.Gross@icrinc.com

Source: Tilray, Inc.

FAQ

What were Tilray's earnings for the first fiscal quarter of 2022?

Tilray reported net revenue of $168 million, a 43% increase year-over-year.

How much did Tilray save in costs from synergies with Aphria?

Tilray achieved approximately $55 million in cost-savings on a run-rate basis and is on track for at least $80 million.

What is Tilray's adjusted EBITDA for the first quarter of 2022?

Tilray's adjusted EBITDA for the first quarter of 2022 was $12.7 million, representing a 58% year-over-year growth.

What is Tilray's market position in Canada and Germany?

Tilray maintains the #1 market share in Canada and is the market leader in Germany for medical cannabis extracts.

What was Tilray's gross profit for the first fiscal quarter of 2022?

Tilray's gross profit increased by 46% to $51 million in the first fiscal quarter of 2022.